Which medication has a national registry to keep track of patients who might develop a serious blood disorder?

Clozapine is the medication that has a national registry to monitor patients for the potential development of agranulocytosis, which is a serious blood disorder characterized by a dangerously low level of neutrophils in the blood. The risk of this adverse effect necessitates careful monitoring of patients who are prescribed clozapine, and hence the establishment of a national registry, often referred to as the Clozapine Risk Evaluation and Mitigation Strategy (REMS) program.

This program helps ensure that patients receive frequent blood tests to check their white blood cell counts (specifically, the absolute neutrophil count, or ANC) before and during their treatment with clozapine. The goal is to promptly identify any blood dyscrasias that could lead to severe complications and to enable timely intervention. This type of rigorous tracking and monitoring illustrates the importance of patient safety protocols in the use of medications with known serious side effects.